LOS ANGELES–(COMMERCIAL THREAD) –Will Labs, a subsidiary of CURE Pharmaceutical Holding Corp. (OTC: CURR) today announced a new advertising campaign and the launch of Seratopical Revolution, a new clean, herbal, technologically advanced, anti-aging and “revolutionary” beauty line.
The line features 11 luxury products that are all made in the USA, available at affordable prices and designed to make you feel younger and hydrated from head to toe. Award-winning actress Nicole Kidman, Sera Labs Strategic Business Partner and Global Brand Ambassador, collaborated with Sera Labs to design the Loving Hands Essential Oil, Indulgence Scrub with Brown Sugar, Face & Neck Harmony Tonic, and Shiny for the ultimate brightening glow. The full range of products can be found at Seratopicalrevolution.com.
âI really wanted to create something that was meaningful to me and that I knew people would really appreciate,â said Kidman, Seratopical’s strategic business partner and global brand ambassador. âThese products are personal to me, from the smell to the texture. I’m so excited to share them with the world and hope everyone loves them as much as we do.
Seratopical Revolution combines nature and science in a range of clean and nourishing beauty products. The range’s Pê«P complex, developed by CURE Pharmaceutical, injects natural herbal ingredients into the deepest layers of the skin using a proprietary tri-peptide delivery system. Unlike other companies that use alcohol as their delivery system, which dries out the skin incredibly, Seratopical Revolution’s natural oil and surfactant delivery systems are effective and provide almost immediate results.
âIt was an amazing race to create this line with Nicole,â said Nancy Duitch, CEO of Sera Labs and Strategic Director of CURE Pharmaceutical. âThere are a lot of beauty companies out there, but the problem is, most of them don’t understand that without an effective delivery system, products sit on your skin and clog your pores. Our proprietary formulators have developed a high-tech delivery system that allows ingredients to penetrate deep into the skin. Our loyal customers will benefit from scientifically proven ingredients that are designed to improve hydration and rejuvenate collagen. Revolution offers a complete body line containing natural plant extracts and peptide blends.
Seratopical Revolution products can be purchased online at seratopicalrevolution.com
Advertising campaign photo and product images: https://www.dropbox.com/sh/o8l39o5xb0yj4bs/AAAj1WTWRwK05EpziP4BJn7ka?dl=0
About Sera Labs
Sera LabsÂ® is a trusted leader in the health, wellness and beauty industries with innovative products featuring cutting edge technology and premium ingredients such as CBD and CBD products. clean plants. Sera Labs creates high quality products that use proprietary formulations based on science. Its more than 20 products are sold under the brands Seratopicâ¢, SeraLabs â¢ and Gordon’s Herbals â¢. Sera Labs sells its products at affordable prices, making them easily accessible globally. Strategically positioned in the growing beauty, health and wellness market categories. Sera Labs products are sold through major national pharmaceutical chains, grocery chains and mass retailers. The company also sells private label products to large retailers and multi-tier merchants, as well as consumer direct (DTC), through online orders on the website, including opt-in subscriptions. For more information visit: Seratopical.com, Seralabshealth.com and follow us on Instagram at @ seratopic, as good as Twitter, and Facebook. Media contact: [email protected]
About CURE Pharmaceutical Holding Corp.
CURE PharmaceuticalÂ® is the pioneering developer of CUREform â¢, a patented drug delivery platform that offers a number of unique immediate and controlled release drug delivery vehicles designed to improve efficacy, safety and effectiveness. patient experience for a wide range of active ingredients.
As a vertically integrated company, CURE’s 25,000 square foot FDA registered and NSFÂ® cGMP certified manufacturing facility enables it to partner with pharmaceutical and wellness companies around the world to a private and white label production. CURE has partnerships in the United States, China, Mexico, Canada, Israel and other markets in Europe.
Statements that CURE makes in this press release may include statements that are not historical fact and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended (âSecurities Actâ), and of Section 21E of the Securities Exchange Act of 1934, as amended (“Exchange Act”), which are generally identified by the use of words such as “anticipates”, “believes”, “believes”, “expects” to “,” intends to “,” may “,” “”, “plans”, “research”, “should”, “will” and variations of these words or similar expressions. CURE intends that such forward-looking statements be covered by the Safe Harbor for Forward-Looking Statements provisions contained in Section 27A of the Securities Act and Section 21E of the Exchange Act and is making this statement for the purpose of comply with these Safe Harbor provisions.
These forward-looking statements include, without limitation, the ability to successfully market the products in partnership, the difficulty of predicting the timing or outcome of related research and development efforts, the characteristics and indications of the products in partnership, the authorizations marketing and launches of other products, the impact of regulation of the pharmaceutical industry, the impact of competitive products and prices, the acceptance and demand of new pharmaceuticals, the impact of patents and others property rights held by competitors and other third parties and the ability to obtain financing on favorable terms. The forward-looking statements contained in this press release reflect CURE’s judgment as of the date of this press release. CURE disclaims any intention or obligation to update these forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy and there will be no sale of our securities in any state or jurisdiction in which such an offer, solicitation or sale would be illegal. prior to registration or qualification under the securities laws of those states or jurisdictions.